Physician profile
Amanda Garner
NPI 1043823792
$4,264.69
in general payments reported to CMS, 2019-2025
30 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $1,125 · 2023: $866 · 2024: $1,194 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,029.21 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $711.21 | 2021-2025 | |
| Lilly USA, LLC | $251.78 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $236.70 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.69 | 2022-2024 | |
| Glaxosmithkline, LLC. | $184.34 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $171.89 | 2021-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $171.01 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $161.25 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.53 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $138.75 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $101.19 | 2023-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $72.50 | 2024-2025 | Resmetirom, Rezdiffra |
| Vanda Pharmaceuticals INC. | $69.62 | 2021-2022 | |
| Amgen INC. | $65.95 | 2022-2024 | Otezla, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.71 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $62.60 | 2023-2024 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $52.32 | 2021-2022 | |
| Organon LLC | $48.00 | 2023 | Nexplanon |
| Sanofi Pasteur INC. | $43.81 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $42.69 | 2021-2023 | Spravato |
| Merck Sharp & Dohme LLC | $39.74 | 2024-2025 | Capvaxive, Vaxneuvance, Vaxelis |
| Novartis Pharmaceuticals Corporation | $32.98 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $27.24 | 2024 | Libtayo |
| Daiichi Sankyo INC. | $23.73 | 2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.09 | 2022 | |
| Mylan Specialty L.P. | $14.74 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $14.58 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $10.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.